Rapid Micro Biosystems, Inc provides a system for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products. The company has developed a differentiated solution for environmental monitoring, water testing and bioburden testing that fully automates a historically manual process.
Microbial Quality Control (MQC) is critical to ensuring sterility of all manufacturing facilities and is mandated by regulatory bodies. However, the standard manual process of microbial testing is time-consuming, resource-intensive, and prone to error. Rapid Micro Biosystems’ technology (the “Growth Direct System”) enables rapid and advanced detection capabilities and enhances efficiency, productivity, and profitability of manufacturing facilities.
The company’s technology has applications across multiple sectors. Specifically, in pharmaceutical manufacturing, it helps to improve reliability and consistency with a direct impact for producers of critical medicines (consistency, reducing manpower, audit, traceability, etc.) and indirect benefits such as reducing waste, faster release times and faster switch-over times when running multiple campaigns in the same facility. With a growing demand for advanced novel therapies that often have very short shelf-lives, Growth Direct System can help expand the availability of these life-saving medicines and/or reduce the cost of producing them.
Rapid Micro Biosystems, Inc is based in Lowell, MA (US) and has a growing customer base in the U.S., Europe and Asia.
See Rapid Micro Biosystems related news here